298 related articles for article (PubMed ID: 38725856)
1. Glycosylation Targeting: A Paradigm Shift in Cancer Immunotherapy.
Ren X; Lin S; Guan F; Kang H
Int J Biol Sci; 2024; 20(7):2607-2621. PubMed ID: 38725856
[TBL] [Abstract][Full Text] [Related]
2. The tumour glyco-code as a novel immune checkpoint for immunotherapy.
RodrÍguez E; Schetters STT; van Kooyk Y
Nat Rev Immunol; 2018 Mar; 18(3):204-211. PubMed ID: 29398707
[TBL] [Abstract][Full Text] [Related]
3. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.
Bader JE; Voss K; Rathmell JC
Mol Cell; 2020 Jun; 78(6):1019-1033. PubMed ID: 32559423
[TBL] [Abstract][Full Text] [Related]
4. The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity.
Wu Z; Li S; Zhu X
Front Immunol; 2021; 12():682435. PubMed ID: 34194437
[TBL] [Abstract][Full Text] [Related]
5. Targeting galectins in T cell-based immunotherapy within tumor microenvironment.
Jin QY; Li YS; Qiao XH; Yang JW; Guo XL
Life Sci; 2021 Jul; 277():119426. PubMed ID: 33785342
[TBL] [Abstract][Full Text] [Related]
6. Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy.
Srivastava A; Rathore S; Munshi A; Ramesh R
AAPS J; 2021 Feb; 23(2):30. PubMed ID: 33586060
[TBL] [Abstract][Full Text] [Related]
7. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape.
Osipov A; Saung MT; Zheng L; Murphy AG
J Immunother Cancer; 2019 Aug; 7(1):224. PubMed ID: 31439034
[TBL] [Abstract][Full Text] [Related]
8. Tumor glucose metabolism and the T cell glycocalyx: implication for T cell function.
Schuurmans F; Wagemans KE; Adema GJ; Cornelissen LAM
Front Immunol; 2024; 15():1409238. PubMed ID: 38881904
[TBL] [Abstract][Full Text] [Related]
9. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
10. Targeting the tumor microenvironment by immunotherapy: part 2.
Leibovici J; Itzhaki O; Huszar M; Sinai J
Immunotherapy; 2011 Nov; 3(11):1385-408. PubMed ID: 22053888
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy.
Guerra L; Bonetti L; Brenner D
Cell Rep; 2020 Jul; 32(1):107848. PubMed ID: 32640218
[TBL] [Abstract][Full Text] [Related]
12. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
[TBL] [Abstract][Full Text] [Related]
13. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.
Lei X; Lei Y; Li JK; Du WX; Li RG; Yang J; Li J; Li F; Tan HB
Cancer Lett; 2020 Feb; 470():126-133. PubMed ID: 31730903
[TBL] [Abstract][Full Text] [Related]
14. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.
Zhu YH; Zheng JH; Jia QY; Duan ZH; Yao HF; Yang J; Sun YW; Jiang SH; Liu DJ; Huo YM
Cell Oncol (Dordr); 2023 Feb; 46(1):17-48. PubMed ID: 36367669
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Carnevalli LS; Ghadially H; Barry ST
Front Immunol; 2021; 12():633685. PubMed ID: 33953710
[TBL] [Abstract][Full Text] [Related]
17. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
[TBL] [Abstract][Full Text] [Related]
19. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy.
Bagaev A; Kotlov N; Nomie K; Svekolkin V; Gafurov A; Isaeva O; Osokin N; Kozlov I; Frenkel F; Gancharova O; Almog N; Tsiper M; Ataullakhanov R; Fowler N
Cancer Cell; 2021 Jun; 39(6):845-865.e7. PubMed ID: 34019806
[TBL] [Abstract][Full Text] [Related]
20. Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy.
Bartish M; Del Rincón SV; Rudd CE; Saragovi HU
Front Immunol; 2020; 11():564499. PubMed ID: 33133075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
